HSBC analyst Rajesh Kumar upgraded Novo Nordisk (NVO) to Buy from Hold with a $70 price target The firm sees a gradual turnaround for Novo as it focuses on reimbursed medical and direct-to-consumer channels. The shares offer an attractive risk/reward into the REDEFINE4 and EVOKE trial readouts in 2026, the analyst told investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Analysts Reaffirm Buy Ratings on Pfizer Stock (PFE) after Trump Pricing Deal
- Novo Nordisk upgraded to Buy from Hold at HSBC
- Moderately bullish activity in Novo Nordisk with shares down 1.23%
- LifeMD offers Ozempic at $499 per month via Novo Nordisk collaboration
- EA acquired in go-private deal for $55B, Carnival reports Q3 beat: Morning Buzz